Arkolith/Insider Trading/BBIO/Form 4

Kumar Neil

Chief Executive Officer, DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed May 19, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
5 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 16, 2026Option exercise(M)34K——268K
May 16, 2026Option exercise(M)20K——288K
May 16, 2026Option exercise(M)12K——299K
May 16, 2026Option exercise(M)7K——306K
May 16, 2026Tax withholding(F)36K$66.13$2.4M269K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 16, 2026Option exercise(M)34K—$0101K
May 16, 2026Option exercise(M)20K—$0137K
May 16, 2026Option exercise(M)12K—$0127K
May 16, 2026Option exercise(M)7K—$098K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000472) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML